Lead Product(s) : Beroterkib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Mosaic Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Mosaic in-Licenses Two Oncology Programs from Astex for Combination Therapies
Details : Under the licensing agreement, Mosaic hold the rights of two clinical programs, which includes ASTX029 (beroterkib). It is being evaluated fr the treatment of neoplasms.
Product Name : ASTX029
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 24, 2025
Lead Product(s) : Beroterkib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Mosaic Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement